GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (NAS:KALV) » Definitions » Shiller PE Ratio

KalVista Pharmaceuticals (KalVista Pharmaceuticals) Shiller PE Ratio : (As of Jun. 03, 2024)


View and export this data going back to 2015. Start your Free Trial

What is KalVista Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


KalVista Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for KalVista Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Shiller PE Ratio Chart

KalVista Pharmaceuticals Annual Data
Trend Dec14 Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of KalVista Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, KalVista Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Shiller PE Ratio falls into.



KalVista Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

KalVista Pharmaceuticals's E10 for the quarter that ended in Jan. 2024 is calculated as:

For example, KalVista Pharmaceuticals's adjusted earnings per share data for the three months ended in Jan. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.84/130.1244*130.1244
=-0.840

Current CPI (Jan. 2024) = 130.1244.

KalVista Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -2.780 99.695 -3.629
201406 -3.635 100.560 -4.704
201409 -5.512 100.428 -7.142
201412 -4.329 99.070 -5.686
201503 -4.760 99.621 -6.217
201506 -5.600 100.684 -7.237
201509 -2.660 100.392 -3.448
201512 -2.100 99.792 -2.738
201603 -3.500 100.470 -4.533
201606 -3.920 101.688 -5.016
201609 -1.260 101.861 -1.610
201701 -1.030 102.456 -1.308
201704 -0.430 103.167 -0.542
201707 -0.510 103.278 -0.643
201710 -0.500 104.070 -0.625
201801 -0.490 104.578 -0.610
201804 -0.061 105.708 -0.075
201807 -0.470 106.324 -0.575
201810 -0.220 106.695 -0.268
201901 -0.230 106.200 -0.282
201904 -0.490 107.818 -0.591
201907 -0.420 108.250 -0.505
201910 -0.330 108.577 -0.395
202001 -0.520 108.841 -0.622
202004 -0.370 108.173 -0.445
202007 -0.610 109.318 -0.726
202010 -0.580 109.861 -0.687
202101 -0.560 110.364 -0.660
202104 -0.650 112.673 -0.751
202107 -0.660 115.183 -0.746
202110 -0.800 116.696 -0.892
202201 -0.920 118.619 -1.009
202204 -0.980 121.978 -1.045
202207 -0.940 125.002 -0.979
202210 -0.900 125.734 -0.931
202301 -0.750 126.223 -0.773
202304 -0.770 127.992 -0.783
202307 -0.740 128.974 -0.747
202310 -0.800 129.810 -0.802
202401 -0.840 130.124 -0.840

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


KalVista Pharmaceuticals  (NAS:KALV) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


KalVista Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals (KalVista Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States.
Executives
Venrock Healthcare Capital Partners Iii, L.p. 10 percent owner 530 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10036
Edward P. Feener officer: Chief Scientific Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Thomas Andrew Crockett director, officer: President and CEO BUILDING 227, TETRICUS SCIENCE PARK, PORTON DOWN, SALISBURY, WILTSHIRE X0 SP4 0JQ
Paul K. Audhya officer: Chief Medical Officer C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Benjamin L Palleiko officer: CFO and Secretary C/O KALVISTA PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLD 200, STE 2203, CAMBRIDGE MA 02139
Christopher Yea officer: Chief Development Officer ONE KENDALL SQUARE, BUILDING 200, SUITE 2203, CAMBRIDGE MA 02139
Albert Cha director 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Patrick Treanor director C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Michael David Smith officer: Senior VP, Development C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE MA 02142
Andreas Maetzel officer: Senior Vice President Medical 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Nancy Stuart director 99 HAYDEN AVENUE, SUITE 500, LEXINGTON MA 02421
Brian Jg Pereira director C/O ADVANCED MAGNETICS, INC., 61 MOONEY STREET, CAMBRIDGE MA 02138
Daniel B Soland director 4560 HORTON STREET,M/S R-422, EMERYVILLE CA 94608
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Sv Life Sciences Fund Iv (gp), L.p. 10 percent owner ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108